Moteur de recherche d’entreprises européennes
Financement de l’UE (4 499 309 €) : Investigation médico-légale innovante via la microfluidique et la génomique unicellulaire Hor 23/07/2025 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Investigation médico-légale innovante via la microfluidique et la génomique unicellulaire
Sexual violence affects 1 in 10 women across Europe and has increased by 10% alone in 2021-2022. Most cases involve complex biological mixtures containing cells from the victim and perpetrator(s). Current forensic methods struggle to isolate individual DNA profiles, leaving many cases unresolved and perpetrators unprosecuted. Addressing these limitations is critical to improving evidence interpretation, ensuring justice for victims, and reducing societal impacts. CapCell aims to deliver a new approach to improve forensics and lawful evidence collection with innovative microfluidics and single-cell genomics technologies to overcome the limitations of mixed DNA evidence. Specifically, we will develop the CapCell toolkit comprised of ten easily integrated modules that capture, select, isolate, sequence and interpret individual cells of interest. We will co-create novel strategies and best practices with end-users and industry to improve evidence collection from postcoital swabs and contact traces. Recovered intact cells from male contributors will then be selected and isolated using innovative mobile microfluidic devices. By employing novel concepts, we will advance follow-up DNA sequencing assays and analysis tools to target diverse forensic biomarkers with single-cell resolution. We will align interpretation frameworks to suit single-cell DNA analysis and leverage machine learning to automate the forensic process. Eventually, CapCell will achieve its goal by validating and implementing the new toolkit (TRL5-7) in the relevant end-user environment, with the support of several forensic science institutes and police forces. To reach its ambitious objectives, CapCell brings together an experienced intersectoral consortium of 13 partners from 8 European countries, with complementary expertise in forensic genomics, biosensor technology, bioinformatics, statistics and technology prototyping. Ultimately, CapCell will contribute to a safer and healthier society across Europe.
| Accelopment Schweiz AG | ? |
| Bundesministerium FUR Inneres | 12 500,00 € |
| Copan Italia S.p.A. | 153 375 € |
| Eesti Kohtuekspertiisi Instituut | 190 113 € |
| I3S - Instituto de Investigacao e Inovacao em Saude da Universidade do Porto | 204 200 € |
| Katholieke Universiteit Leuven | 1 618 326 € |
| Medizinische Universitat Innsbruck | 597 384 € |
| Netherlands Forensic Institute | 446 098 € |
| Nimagen B.V. | 91 128 € |
| Politsei- ja Piirivalveamet | 95 049 € |
| Universiteit Maastricht | 886 763 € |
| Voxdale | 204 375 € |
https://cordis.europa.eu/project/id/101225737
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : accelopment Schweiz AG, Zurich, Suisse.